A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists
Part of paid clinical trials in Rochester, New York.
- Sponsor
- University of Rochester
- Study ID
- NCT05335369
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 60 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- UR-GOAL — BEHAVIORALUR-GOAL helps conducts assessments of fitness, elicits patient values via Best-Worst Scaling, and elicits preferences for prognostic information and assesses prognostic awareness. The tool also includes an AML educational video.
Study Details
The objective of this study is to evaluate the preliminary efficacy of the UR-GOAL tool in improving shared decision making and communication between older patients with AML and their oncologists in a pilot randomized trial.
Key Dates
- Start date
- Jun 17, 2022
- Status verified
- Mar 2026
- Primary completion
- Apr 7, 2025
- Completion
- Oct 6, 2025
Study Design
- Enrollment
- 161 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- No Intervention: Usual careUsual care
- Experimental: UR-GOALUR-GOAL helps conducts assessments of fitness, elicits patient values via Best-Worst Scaling, and elicits preferences for prognostic information and assesses prognostic awareness. The tool also includes an AML educational video.
Primary Outcome Measure
Shared Decision Making [ Time Frame: Within 1-4 weeks after treatment initiation ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Rochester | Rochester | New York | 14642 | - |
Find similar trials in Rochester, NY
By condition
By specialty
By research site
Related Studies
- Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic SyndromeRecruiting · University of Rochester · Rochester, New York
- KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT ChildrenPHASE2 · Enrolling By Invitation · Michael Pulsipher · Los Angeles, California
- A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesPHASE1 · Recruiting · Orca Biosystems, Inc. · Duarte, California
- Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) TransplantEARLY_PHASE1 · Recruiting · Omar Aljitawi · Rochester, New York